Chip-Based Mobile Blood Diagnosis Takes Only Minutes
|
By LabMedica International staff writers Posted on 22 Oct 2009 |
New analysis technology takes just a few minutes, and physicians know immediately whether there are any pathogens in the blood. The improved marker-free technique provides the basis for faster analysis, whether in a hospital or for mobile blood donations.
If a person loses a large amount of blood, the consequences can be critical. That is why adequate quantities of donated blood have to be kept available in hospitals and blood banks. In Egypt, doctors collect blood by traveling to towns and villages and conducting blood donation sessions in a laboratory bus. The problem is that 25% of the samples taken contain pathogens, including HIV, hepatitis, and syphilis. As these diseases can be passed on in transfusions, the contaminated blood cannot be used. Conventional fast tests are not suitable in most cases for mobile use.
In the near future, a rapid and robust analysis technique should help. A few drops of blood could be tested in the bus to check whether it can be used. Only if the result is positive will physicians take a larger quantity from the donor. The basis for this has been provided by research scientists from the Fraunhofer Institute for Biomedical Engineering IBMT (Sankt Ingbert, Germany) under a European Union (EU) project also involving the Egyptian company Vacsera (Giza), Mivitec, GmbH (Munich, Germany), the Institute for Analytical Sciences ISAS (Dortmund, Germany), and the University of Lausitz (Germany). "Our consortium has developed a glass chip which has antibodies on it. Tiny surface oscillations are induced in the chip. If the relevant virus binds with an antibody, the oscillation changes,” explained Dr. Thomas Velten, head of department at the IBMT.
The technique is not new, but the new chip that has been developed offers advantages. Usually there is only one measurement field and a reference field next to it, positioned a just a few millimeters apart. But the temperature there can be different. On the new chip, the measurement and reference fields are divided into narrow strips, which in each case are located right next to each other. As a result, the chip is more resistant to fluctuations in temperature. Moreover, the new chip consists of four analysis squares, which means that the blood can be examined for four different pathogens during each test.
It has also been difficult up until now for laboratory workers to avoid contact with the blood and protect themselves from infections while conducting tests in the bus. The researchers at the IBMT have therefore encapsulated the chip. This makes the blood follow a defined course on the chip, protecting the user.
A first prototype of the measurement device is being presented at the Medica trade fair from November 18-21, 2009, in Düsseldorf, Germany.
Dr. Velten estimates that the device could come onto the market in approximately three years' time.
Related Links:
Fraunhofer Institute for Biomedical Engineering IBMT
Vacsera
Mivitec
Institute for Analytical Sciences ISAS
If a person loses a large amount of blood, the consequences can be critical. That is why adequate quantities of donated blood have to be kept available in hospitals and blood banks. In Egypt, doctors collect blood by traveling to towns and villages and conducting blood donation sessions in a laboratory bus. The problem is that 25% of the samples taken contain pathogens, including HIV, hepatitis, and syphilis. As these diseases can be passed on in transfusions, the contaminated blood cannot be used. Conventional fast tests are not suitable in most cases for mobile use.
In the near future, a rapid and robust analysis technique should help. A few drops of blood could be tested in the bus to check whether it can be used. Only if the result is positive will physicians take a larger quantity from the donor. The basis for this has been provided by research scientists from the Fraunhofer Institute for Biomedical Engineering IBMT (Sankt Ingbert, Germany) under a European Union (EU) project also involving the Egyptian company Vacsera (Giza), Mivitec, GmbH (Munich, Germany), the Institute for Analytical Sciences ISAS (Dortmund, Germany), and the University of Lausitz (Germany). "Our consortium has developed a glass chip which has antibodies on it. Tiny surface oscillations are induced in the chip. If the relevant virus binds with an antibody, the oscillation changes,” explained Dr. Thomas Velten, head of department at the IBMT.
The technique is not new, but the new chip that has been developed offers advantages. Usually there is only one measurement field and a reference field next to it, positioned a just a few millimeters apart. But the temperature there can be different. On the new chip, the measurement and reference fields are divided into narrow strips, which in each case are located right next to each other. As a result, the chip is more resistant to fluctuations in temperature. Moreover, the new chip consists of four analysis squares, which means that the blood can be examined for four different pathogens during each test.
It has also been difficult up until now for laboratory workers to avoid contact with the blood and protect themselves from infections while conducting tests in the bus. The researchers at the IBMT have therefore encapsulated the chip. This makes the blood follow a defined course on the chip, protecting the user.
A first prototype of the measurement device is being presented at the Medica trade fair from November 18-21, 2009, in Düsseldorf, Germany.
Dr. Velten estimates that the device could come onto the market in approximately three years' time.
Related Links:
Fraunhofer Institute for Biomedical Engineering IBMT
Vacsera
Mivitec
Institute for Analytical Sciences ISAS
Latest Hematology News
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
- Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
Rapid identification of Ebola infections is essential to limit transmission and guide public health response, yet detection can be difficult when outbreaks involve rare variants. The current outbreaks... Read more
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read more
Automated Blood Culture System Speeds Detection of Bloodstream Infections
Bloodstream infections and sepsis require rapid laboratory detection to guide targeted antimicrobial therapy and reduce mortality. Conventional blood culture workflows can delay actionable results by critical... Read morePathology
view channel
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read more
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Collaboration Advances ctDNA-Guided Development in Metastatic Colorectal Cancer
Natera, Inc. (Austin, TX, USA) and CytoDyn Inc. (Vancouver, WA, USA) announced a strategic collaboration focused on metastatic colorectal cancer (mCRC). Under the agreement, Natera will evaluate circulating... Read more








